Welcome to BioMarket Group!

Commercial Insight Top 20 cancer therapy brands forecast

Additional Information

Published Date Oct 12, 2010
Special Offer No
Pages No
PDF Fact Sheet View Fact Sheet for the report Commercial Insight Top 20 cancer therapy brands forecast in PDF format.
Published on Date No
Format Interactive Model
Publisher Datamonitor
Product Line No
Full Title No

Availability: In stock

$15,200.00

Quick Overview

The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy sales. The commercial success experienced by the key companies in...
Request free sample pages from Commercial Insight Top 20 cancer therapy brands forecast



The top 20 cancer therapies achieved sales of over $30 billion in 2009 accounting for 75% of all cancer therapy sales. The commercial success experienced by the key companies in the cancer therapy market makes the market extremely attractive to drug developers. The entire branded cancer therapies market will grow from $40.6 billion in 2009 to $57.2 billion in 2019 at a CAGR of 3.5%.

Reasons to Purchase

*Quantify the performance of each of the top 20 cancer therapy brands in the seven major markets in 2009 and 2019

*Acquire a detailed account of top-selling cancer brand dynamics and the events that drive and limit their market growth

*Acquire a detailed account of the key developers in the cancer therapy market and their forecast performance in the 7MM over the period 2009-2019

#N/A

Request free sample pages from Commercial Insight Top 20 cancer therapy brands forecast

Other selected research from the 'Commercial Insight' category:


Commercial Insight: Vaccines - Reaching Adulthood
The vaccine sector has historically been dominated by five key companies, which derived value from high volume sales or relatively cheap commodity vaccine products. However, recent years have seen the introduction of higher-value offerings, such as Wyeth`s Prevnar, and the involvement of a greater number of smaller vaccine players, changing the dynamics of this sector. Learn More


Commercial Insight: Antihormonal Therapies Aromatase Inhibitors Reinvigorate a Mature Market
The antihormonal cancer therapy market is characterized by a mature nature and a relatively high level of saturation. Despite this, growth will continue slowly at a CAGR of 0.9% during 2004-14, with those areas in decline offset by clear potential from new products and line extensions. Generic competition continues to threaten, although effective lifecycle management can dilute the overall impact. Learn More

Other selected research from the 'Oncology' category:


Stakeholder Opinions: Primary Brain Cancer
Key issues in the primary brain cancer market, including forecast epidemiology data, current treatment patterns and controversies, unmet needs, insight into pipeline activity and key stakeholder opinions. The report focuses in particular on glioma. Learn More


Molecular Diagnostics in Cancer Testing
Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being continually added.

The technologies that come under the umbrella of molecular diagnostics include...
Learn More